Journal
HEPATO-GASTROENTEROLOGY
Volume 58, Issue 112, Pages 1933-1936Publisher
H G E UPDATE MEDICAL PUBLISHING S A
DOI: 10.5754/hge11186
Keywords
Smad4; Colorectal cancer; Carcinogenesis; Prognosis
Categories
Funding
- Hanyang University Research Fund, Seoul, Korea [2007-6725]
Ask authors/readers for more resources
Background/Aims: Loss of Smad4 function is associated with the acquisition of advanced colorectal cancer phenotypes. We investigated the role of Smad4 as a prognostic marker after curative therapy. Methodology: Four hundred and twenty nine consecutive colorectal cancers were analyzed by tissue microarray-based immunohistochemical assay. Results: Smad4 protein was expressed in 61.5% (24/39), 53.1% (77/145), 41.3% (78/189) and 34.8% (16/46) of stage I, II, III and IV cancers, respectively. Lymphovascular invasion and lymph node metastasis were strongly correlated with the loss of Smad4 expression (p<0.0001 and p=0.002, respectively). Disease-free survival did not differ between Smad4-positive and Smad4-negative cancers. In stage Ill disease, time to recurrence after curative therapy was shorter in the Smad4-negative than in the Smad4-positive cancers (20.1 +/- 15.1 vs. 34.6 +/- 34.1 months, p=0.035). Conclusions: Smad4 protein is of no value in predicting recurrence after curative therapy in colorectal cancer, but it may be helpful in identifying a subset of patients with early recurrence after curative therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available